ArticleScientific reports2026
Efficacy of a combined reverse and modified Valsalva maneuver for the cardioversion of paroxysmal supraventricular tachycardia: a retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To evaluate the efficacy of a combined sequential reverse Valsalva maneuver (RVM) and modified Valsalva maneuver (MVM) compared to the MVM alone for terminating paroxysmal supraventricular tachycardia (PSVT). A multicenter, retrospective cohort study was conducted at four hospitals in China between January 2022 and March 2025. Hemodynamically stable adult patients with ECG-confirmed PSVT were included. Patients were categorized into two groups based on the initial treatment received: a Combined VM group (sequential RVM followed by MVM) and a Modified VM Alone group. The primary outcome was successful cardioversion to sinus rhythm on the first attempt. Secondary outcomes included cumulative success, need for rescue medication, and adverse events. A multivariable logistic regression analysis was performed to adjust for potential confounders, including age, sex, baseline heart rate, prior PSVT history, tachycardia subtype, body mass index, hypertension, and diabetes mellitus. A total of 208 patients were included in the analysis. The baseline characteristics were similar between the two groups. The first-attempt cardioversion success rate was significantly higher in the Combined VM group than in the Modified VM Alone group (59.2% vs. 35.2%; absolute difference, 24.0%; 95% CI, 10.8% to 37.2%; P < 0.001). After multivariable adjustment, the Combined VM group remained independently associated with a significantly higher likelihood of first-attempt cardioversion success (adjusted odds ratio [aOR], 2.79; 95% CI, 1.56 to 4.98; P < 0.001). The cumulative success rate after up to three attempts was also higher in the Combined VM group (80.6% vs. 59.0%; P = 0.001), which was associated with a significantly lower need for rescue medication (19.4% vs. 41.0%; P = 0.001). No serious adverse events were reported. In this retrospective study, a combined strategy of a reverse Valsalva maneuver followed by a modified Valsalva maneuver was associated with a significantly higher rate of successful cardioversion for PSVT compared to the modified Valsalva maneuver alone. This association persisted after adjustment for clinically relevant confounders. These findings suggest the potential of this novel, no-cost maneuver, and warrant confirmation in a large-scale randomized controlled trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.